v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues:    
Research and other $ 494 $ 375
Revenue, Product and Service [Extensible Enumeration] nwbo:ResearchAndOtherRevenueMember nwbo:ResearchAndOtherRevenueMember
Operating costs and expenses:    
Research and development $ 4,858 $ 8,351
General and administrative 6,536 9,335
Total operating costs and expenses 11,394 17,686
Loss from operations (10,900) (17,311)
Other income (expense):    
Settlement gain 2,250  
Change in fair value of derivative liabilities 9,416 1,280
Change in fair value of share payable 201 (23)
Change in fair value of convertible notes 5,235 3,697
Loss from extinguishment of debt (4,756) (7,282)
Loss from issuance of debt (738)  
Inducement expense (87)  
Interest expense (2,346) (1,602)
Foreign currency transaction gain (loss) (1,344) 1,898
Total other income (expense) 7,831 (2,032)
Net loss (3,069) (19,343)
Deemed dividend related to warrant modifications (331) (265)
Net loss attributable to common stockholders (3,400) (19,608)
Other comprehensive income (loss)    
Foreign currency translation adjustment 496 (1,644)
Total comprehensive loss $ (2,904) $ (21,252)
Net loss per share applicable to common stockholders, Basic (in dollars per share) $ 0 $ (0.01)
Net loss per share applicable to common stockholders, Diluted (in dollars per share) $ 0 $ (0.01)
Weighted average shares used in computing basic loss per share (in shares) 1,584,843 1,359,496
Weighted average shares used in computing diluted loss per share (in shares) 1,584,843 1,359,496